Targeting Nuclear Export in Cancer | Karyopharm · Turner Oncotarget 2016: Epub_ 4. Conforti et...

25

Transcript of Targeting Nuclear Export in Cancer | Karyopharm · Turner Oncotarget 2016: Epub_ 4. Conforti et...

Page 1: Targeting Nuclear Export in Cancer | Karyopharm · Turner Oncotarget 2016: Epub_ 4. Conforti et Clin CancerRes_ 2015;21-4508-4513_ Study Objectives Primary objectives MTD and RP2D
Page 2: Targeting Nuclear Export in Cancer | Karyopharm · Turner Oncotarget 2016: Epub_ 4. Conforti et Clin CancerRes_ 2015;21-4508-4513_ Study Objectives Primary objectives MTD and RP2D
Page 3: Targeting Nuclear Export in Cancer | Karyopharm · Turner Oncotarget 2016: Epub_ 4. Conforti et Clin CancerRes_ 2015;21-4508-4513_ Study Objectives Primary objectives MTD and RP2D
Page 4: Targeting Nuclear Export in Cancer | Karyopharm · Turner Oncotarget 2016: Epub_ 4. Conforti et Clin CancerRes_ 2015;21-4508-4513_ Study Objectives Primary objectives MTD and RP2D
Page 5: Targeting Nuclear Export in Cancer | Karyopharm · Turner Oncotarget 2016: Epub_ 4. Conforti et Clin CancerRes_ 2015;21-4508-4513_ Study Objectives Primary objectives MTD and RP2D
Page 6: Targeting Nuclear Export in Cancer | Karyopharm · Turner Oncotarget 2016: Epub_ 4. Conforti et Clin CancerRes_ 2015;21-4508-4513_ Study Objectives Primary objectives MTD and RP2D
Page 7: Targeting Nuclear Export in Cancer | Karyopharm · Turner Oncotarget 2016: Epub_ 4. Conforti et Clin CancerRes_ 2015;21-4508-4513_ Study Objectives Primary objectives MTD and RP2D
Page 8: Targeting Nuclear Export in Cancer | Karyopharm · Turner Oncotarget 2016: Epub_ 4. Conforti et Clin CancerRes_ 2015;21-4508-4513_ Study Objectives Primary objectives MTD and RP2D
Page 9: Targeting Nuclear Export in Cancer | Karyopharm · Turner Oncotarget 2016: Epub_ 4. Conforti et Clin CancerRes_ 2015;21-4508-4513_ Study Objectives Primary objectives MTD and RP2D
Page 10: Targeting Nuclear Export in Cancer | Karyopharm · Turner Oncotarget 2016: Epub_ 4. Conforti et Clin CancerRes_ 2015;21-4508-4513_ Study Objectives Primary objectives MTD and RP2D
Page 11: Targeting Nuclear Export in Cancer | Karyopharm · Turner Oncotarget 2016: Epub_ 4. Conforti et Clin CancerRes_ 2015;21-4508-4513_ Study Objectives Primary objectives MTD and RP2D
Page 12: Targeting Nuclear Export in Cancer | Karyopharm · Turner Oncotarget 2016: Epub_ 4. Conforti et Clin CancerRes_ 2015;21-4508-4513_ Study Objectives Primary objectives MTD and RP2D
Page 13: Targeting Nuclear Export in Cancer | Karyopharm · Turner Oncotarget 2016: Epub_ 4. Conforti et Clin CancerRes_ 2015;21-4508-4513_ Study Objectives Primary objectives MTD and RP2D
Page 14: Targeting Nuclear Export in Cancer | Karyopharm · Turner Oncotarget 2016: Epub_ 4. Conforti et Clin CancerRes_ 2015;21-4508-4513_ Study Objectives Primary objectives MTD and RP2D
Page 15: Targeting Nuclear Export in Cancer | Karyopharm · Turner Oncotarget 2016: Epub_ 4. Conforti et Clin CancerRes_ 2015;21-4508-4513_ Study Objectives Primary objectives MTD and RP2D
Page 16: Targeting Nuclear Export in Cancer | Karyopharm · Turner Oncotarget 2016: Epub_ 4. Conforti et Clin CancerRes_ 2015;21-4508-4513_ Study Objectives Primary objectives MTD and RP2D
Page 17: Targeting Nuclear Export in Cancer | Karyopharm · Turner Oncotarget 2016: Epub_ 4. Conforti et Clin CancerRes_ 2015;21-4508-4513_ Study Objectives Primary objectives MTD and RP2D
Page 18: Targeting Nuclear Export in Cancer | Karyopharm · Turner Oncotarget 2016: Epub_ 4. Conforti et Clin CancerRes_ 2015;21-4508-4513_ Study Objectives Primary objectives MTD and RP2D
Page 19: Targeting Nuclear Export in Cancer | Karyopharm · Turner Oncotarget 2016: Epub_ 4. Conforti et Clin CancerRes_ 2015;21-4508-4513_ Study Objectives Primary objectives MTD and RP2D
Page 20: Targeting Nuclear Export in Cancer | Karyopharm · Turner Oncotarget 2016: Epub_ 4. Conforti et Clin CancerRes_ 2015;21-4508-4513_ Study Objectives Primary objectives MTD and RP2D
Page 21: Targeting Nuclear Export in Cancer | Karyopharm · Turner Oncotarget 2016: Epub_ 4. Conforti et Clin CancerRes_ 2015;21-4508-4513_ Study Objectives Primary objectives MTD and RP2D
Page 22: Targeting Nuclear Export in Cancer | Karyopharm · Turner Oncotarget 2016: Epub_ 4. Conforti et Clin CancerRes_ 2015;21-4508-4513_ Study Objectives Primary objectives MTD and RP2D
Page 23: Targeting Nuclear Export in Cancer | Karyopharm · Turner Oncotarget 2016: Epub_ 4. Conforti et Clin CancerRes_ 2015;21-4508-4513_ Study Objectives Primary objectives MTD and RP2D
Page 24: Targeting Nuclear Export in Cancer | Karyopharm · Turner Oncotarget 2016: Epub_ 4. Conforti et Clin CancerRes_ 2015;21-4508-4513_ Study Objectives Primary objectives MTD and RP2D
Page 25: Targeting Nuclear Export in Cancer | Karyopharm · Turner Oncotarget 2016: Epub_ 4. Conforti et Clin CancerRes_ 2015;21-4508-4513_ Study Objectives Primary objectives MTD and RP2D

PRODUCTS Technical Support, Review & Audit & SERVICES · Rigging, Lifting & Slinging Meets & Exceeds API RP2D Rev. 6 (LOLER is available) Designed to teach delegates about the technical

PRODUCTS Technical Support, Review & Audit & SERVICES · Rigging, Lifting & Slinging Meets & Exceeds API RP2D Rev. 6 (LOLER is available) Designed to teach delegates about the technical

Investor Conference Call: American Society of Hematology (ASH) … · 2020. 12. 8. · American Society of Hematology (ASH) 2020 ©2020 Karyopharm Therapeutics Inc. 2. ... In addition,

Investor Conference Call: American Society of Hematology (ASH) … · 2020. 12. 8. · American Society of Hematology (ASH) 2020 ©2020 Karyopharm Therapeutics Inc. 2. ... In addition,

Safety and Efficacy of the Combination of Selinexor ... · Primary Objective: Determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) Patient Populations: •Arm

Safety and Efficacy of the Combination of Selinexor ... · Primary Objective: Determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) Patient Populations: •Arm

J MM Journal of Menopausal Medicine 2015;21:115-119 · 2015-09-04 · 115 Introduction Sclerosing stromal tumor (SST) is a rare benign ovarian neoplasm of the sex cord stromal category

J MM Journal of Menopausal Medicine 2015;21:115-119 · 2015-09-04 · 115 Introduction Sclerosing stromal tumor (SST) is a rare benign ovarian neoplasm of the sex cord stromal category

AACR 2012 Poster Session. Abstract #1914 1 - Karyopharm · 2019. 5. 8. · A375 uM Drug SK-MEL-5 0.1 uM D rug co MEWO KPT.251 + KPT 0.1 g" Drug co BRAF WILD-TYPE BRAF MUTANTV600E

AACR 2012 Poster Session. Abstract #1914 1 - Karyopharm · 2019. 5. 8. · A375 uM Drug SK-MEL-5 0.1 uM D rug co MEWO KPT.251 + KPT 0.1 g" Drug co BRAF WILD-TYPE BRAF MUTANTV600E

2711P-IN004J-EN-P, Logic Module, Internal CompactFlash ... · 2711P-RP2A Logic module with 128 MB flash/128 MB RAM, AC input(2) 2711P-RP2D Logic module with 128 MB flash/ 128 MB RAM,

2711P-IN004J-EN-P, Logic Module, Internal CompactFlash ... · 2711P-RP2A Logic module with 128 MB flash/128 MB RAM, AC input(2) 2711P-RP2D Logic module with 128 MB flash/ 128 MB RAM,

JP Morgan Healthcare Conference 2021 · 2021. 1. 11. · JP Morgan Healthcare Conference 2021. Michael G. Kauffman, MD, PhD, Chief Executive Officer . January 11, 2021. 2 ©2021 KARYOPHARM

JP Morgan Healthcare Conference 2021 · 2021. 1. 11. · JP Morgan Healthcare Conference 2021. Michael G. Kauffman, MD, PhD, Chief Executive Officer . January 11, 2021. 2 ©2021 KARYOPHARM

Slings - Bishop Lifting Products · PDF fileSlings 18 Slings SLGS Double Leg Type: D Features: • Heavy gauge stainless steel tag in accordance with ASME B30.9 and API RP2D • Proof

Slings - Bishop Lifting Products · PDF fileSlings 18 Slings SLGS Double Leg Type: D Features: • Heavy gauge stainless steel tag in accordance with ASME B30.9 and API RP2D • Proof

72x36 Poster Template - Karyopharm · NAD/NADH-Glo and Celltiter-Glo were used to measure NAD and ATP levels, respectively. Gene expression and gene ... KPT-9274 200 mg/kg ooDx3 Niacin

72x36 Poster Template - Karyopharm · NAD/NADH-Glo and Celltiter-Glo were used to measure NAD and ATP levels, respectively. Gene expression and gene ... KPT-9274 200 mg/kg ooDx3 Niacin

Operation and Maintenance of Offshore Cranes - Web Designlinux.geodatapub.com/shipwebpages/deck/Crane operations API RP2D... · G.1 Rated Sling Capacity Calculation ... semi-submersible

Operation and Maintenance of Offshore Cranes - Web Designlinux.geodatapub.com/shipwebpages/deck/Crane operations API RP2D... · G.1 Rated Sling Capacity Calculation ... semi-submersible

Statistical Analysis Plan (SAP)...Protocol A8081054 Statistical Analysis Plan Page 7 Dose Expansion Phase Cohort Once the MTD(or the RP2D)for the combination has been defined, up to

Statistical Analysis Plan (SAP)...Protocol A8081054 Statistical Analysis Plan Page 7 Dose Expansion Phase Cohort Once the MTD(or the RP2D)for the combination has been defined, up to

Targeting CRM1 in AML - Karyopharm...(TKIs: Gleevec, Tarceva, Ibrutinib) Inhibition of Invasion and Metastasis (Experimental Agents) Tumor Suppressor Activation (Selinexor, MDM2 Inhibitors)

Targeting CRM1 in AML - Karyopharm...(TKIs: Gleevec, Tarceva, Ibrutinib) Inhibition of Invasion and Metastasis (Experimental Agents) Tumor Suppressor Activation (Selinexor, MDM2 Inhibitors)

The Evolution of Submission and RIM Processes at Karyopharm › wp-content › uploads › 2016 › 04 › ... · which ultimately drives process evolution –Change is GOOD. Implementation

The Evolution of Submission and RIM Processes at Karyopharm › wp-content › uploads › 2016 › 04 › ... · which ultimately drives process evolution –Change is GOOD. Implementation

Making precision medicine a reality for multiple myeloma ...of a Biotech Investment Award in 2010 to the drug’s developer, Karyopharm. The lead MMRC investigator is Andrej Jakubowiak,

Making precision medicine a reality for multiple myeloma ...of a Biotech Investment Award in 2010 to the drug’s developer, Karyopharm. The lead MMRC investigator is Andrej Jakubowiak,

New Treatment Options in Ovarian Cancer - ENGAGeO · New Treatment Options in Ovarian Cancer. Mansoor Raza Mirza Disclosures (last 24 months) Board of Directors: Karyopharm Therapeutics

New Treatment Options in Ovarian Cancer - ENGAGeO · New Treatment Options in Ovarian Cancer. Mansoor Raza Mirza Disclosures (last 24 months) Board of Directors: Karyopharm Therapeutics

RP2B/RP2D/RP4B/RP4D...1. Remove the battery from the printer then remove the red battery isolator. 2. Reinstall the battery in the printer. Align the release tab with the same side

RP2B/RP2D/RP4B/RP4D...1. Remove the battery from the printer then remove the red battery isolator. 2. Reinstall the battery in the printer. Align the release tab with the same side

Prevalence of and potential influencing factors for ... Anderson et al 2015... · Research Report Eur Addict Res 2015;21:6–18 DOI: 10.1159/000365284 Prevalence of and Potential

Prevalence of and potential influencing factors for ... Anderson et al 2015... · Research Report Eur Addict Res 2015;21:6–18 DOI: 10.1159/000365284 Prevalence of and Potential

J MM Journal of Menopausal Medicine 2015;21:56-59 · abdominal distention. Her obstetric history included three uncomplicated deliveries and menopause occurred at the age of 52 years.

J MM Journal of Menopausal Medicine 2015;21:56-59 · abdominal distention. Her obstetric history included three uncomplicated deliveries and menopause occurred at the age of 52 years.

1 USER’S GUIDE LIFTING API RP2D Version (06/06 ...primelevelconsulting.com/toolbox/crosbyriggingcardapi.pdfALL PERSONNEL ARE IN THE CLEAR BEFORE LEAVING THE CONTROL STATION FOR PROLONGED

1 USER’S GUIDE LIFTING API RP2D Version (06/06 ...primelevelconsulting.com/toolbox/crosbyriggingcardapi.pdfALL PERSONNEL ARE IN THE CLEAR BEFORE LEAVING THE CONTROL STATION FOR PROLONGED

J MM Journal of Menopausal Medicine 2015;21:47-55 · 9.8%), intraperitoneal large tumors (18 patients, 7.3%), and asymptomatic uterine myoma (86 patients, 35%). For patients with

J MM Journal of Menopausal Medicine 2015;21:47-55 · 9.8%), intraperitoneal large tumors (18 patients, 7.3%), and asymptomatic uterine myoma (86 patients, 35%). For patients with